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ABSTRACT
Background: The development of port-site metastases
following laparoscopic resection of various malignancies
continues to be a disturbing issue for laparoscopic sur-
geons. Previous studies revealed promising results with
oxaliplatin, a third-generation platinum compound, as a
first-line treatment in advanced colorectal cancer. This
study evaluates the effect of topical application of oxali-
platin on the development of port-site metastases in an
experimental murine model.
Methods: Nineteen female BDIX rats (immunocompe-
tent, 6 weeks old) underwent a sham laparoscopic oper-
ation after 1x10
7 viable rat colon carcinoma viable cells
(LMCR) had been injected into their peritoneal cavities.
Three trocars (1 central camera port and 2 additional
lateral ports) were introduced into the abdomen, and a
pneumoperitoneum was created with carbon dioxide. Ten
minutes after LMCR, cells were injected into the peritoneal
cavity, the 2 lateral trocars were removed and carbon
dioxide insufflation was maintained for an additional 5
minutes to allow for tumor cell seeding. Oxaliplatin (0.198
mg/kg) was then topically applied to 1 trocar site intra-
muscularly, while the other site was left untreated. One
week later, the animals were euthanized, and the port
sites were histologically examined for evidence of metas-
tases.
Results: The rate of tumor implantation at the muscle
layer in control sites was 68% (13/19) compared with 37%
(7/19) at oxaliplatin-treated sites (P0.1). Also, no signif-
icant differences were detected in port-site metastasis
rates in other untreated layers of the abdominal wall.
Conclusion: Intramuscular topical application of oxali-
platin may not decrease the incidence of port-site metas-
tasis in a syngeneic animal model of colon cancer. Nev-
ertheless, we can see the tendency of declination. Further
studies are needed to better determine its possible thera-
peutic role in high-risk humans undergoing laparoscopic
resection of colorectal malignancies.
Key Words: Laparoscopy, Oxaliplatin, Wound, Metasta-
sis, Colorectal cancer, Port-site metastases.
INTRODUCTION
Laparoscopic surgery for malignancy continues to be a
matter of contention. While in the beginning of the lapa-
roscopic era, the major concern was focused on technical
feasibility, it was not until several reports describing port-
site recurrences appeared,1–4 that the applicability of lapa-
roscopy in these cases was questioned. Multiple publica-
tions have demonstrated the advantage of laparoscopy
over open surgery regarding postoperative recovery and
better cosmetics5–7; however, questions as to adequacy of
resection, long-term oncological outcome and port-site
recurrences, limited its application in cancer surgery. Re-
cently, several studies showed that the oncological results
are, at least, the same as in open surgery, and surprisingly
the rates of port-site metastasis were comparable.7–10 The
real incidence of this particular way of tumor spreading is
not known, nor is its prognostic implication. It seems that
in experienced hands the incidence does not significantly
differ from that in open surgery.7,9,10 However, since the
greater bulk of procedures is not performed by highly
skilled laparoscopic surgeons, this continues to pose a
problem that should be addressed during surgery. None-
theless, even though its occurrence is considered low
(1.1% to 3.9%),11,12 overall it is still higher than what is
expected for open surgery (0.6% to 0.8%).11
The mechanisms proposed for this unwarranted phenom-
enon include excessive manipulation of the tumor, CO2
insufflation, air leakage through port sites (desufflation),
direct implantation with contaminated instruments, and
contamination while extracting the specimen.13 However,
the precise mechanism is not known yet. Nonetheless,
Department of Surgery, New York Presbyterian Hospital, Weill-Cornell College of
Medicine, New York, New York, USA (all authors).
We thank Fundacion Bunge y Born in Buenos Aires, Argentina for support of this
research.
Address reprint requests to: Michel Gagner, MD, FRCSC, FACS, Chief, Bariatric
Surgery, Weill-Cornell College of Medicine, New York-Presbyterian Hospital, 525 E
68th St, Box 129, New York, NY 10021, USA. Telephone: 212 746 5294, Fax: 212 746
5236, E-mail: mig2016@med.cornell.edu
© 2006 by JSLS, Journal of the Society of Laparoendoscopic Surgeons. Published by
the Society of Laparoendoscopic Surgeons, Inc.
JSLS (2006)10:160–165 160
SCIENTIFIC PAPERwhile most of these causes can, theoretically, be pre-
vented through better surgical technique and experience,
it has been noted that tumor cells are being spilled in
almost half of the patients undergoing open cancer sur-
gery.14 This fact has drawn the attention of several inves-
tigators, who published a number of articles addressing
this issue.11,13,15–18 Some therapeutic agents have been
tested including Povidine Iodine and 5-FU, which showed
significant potency in preventing tumor growth at port
sites,11,16,17,19 but none displayed a total protection. In
those studies, intraperitoneal irrigation or systemic admin-
istration of cytotoxic agent might prevent tumor implan-
tation after laparoscopic surgery and port-site metastases.
The use of intraperitoneal heparin also can prevent tumor
implantation by reducing the presence of intraperitoneal
blood.18
On August 2002, the FDA approved oxaliplatin for the
treatment of colorectal cancer in those patients refractory
to 5-FU and Irinotecan. This new drug has been demon-
strated to be effective in the treatment of patients with
colorectal cancer.20 The aim of our study was to evaluate
the efficacy of this new cytotoxic drug as a topical treat-
ment to prevent port-site metastasis following laparo-
scopic surgery for colorectal cancer.
METHODS
Cell Cultures and Animals
A metastatic rat colon carcinoma cell line (LMCR) with
Sialyl-Tn (STn) negative clones was used in this study. The
cell line was originally derived in the Gastrointestinal
Research Laboratory, Department of Medicine, Mount Si-
nai School of Medicine.21 The cell line was grown in
DMEM supplemented with 10% fetal calf serum, 50
units/mL penicillin, and 50 g/mL streptomycin and incu-
bated at 37°C in 7.5% CO2. Nineteen female BDIX rats (4
to 6 weeks old) obtained from Charles River Laboratories
through the National Cancer Institute were used. This
number of animals will allow detection of a difference of
50% in the incidence of port-site metastasis (80% for con-
trol group and 30% for each group)11 with power 0.80 for
a 2-sided test at the 0.05 level of significance. Our Insti-
tutional Animal Care and Use Committee approved the
study.
Cytotoxicity Assays
To determine the optimal concentration of oxaliplatin for
use in the animal experiment, the oxaliplatin concentra-
tion that inhibits 50% of cell growth (IC50) was determined
by using an MTT (3, 4, 5-dimethylthiazool-2, 5-diphe-
nyltetrazolium bromide; Sigma) assay. 4x10
3, 8x10
3, and
1.2x10
4 cells/well were seeded into a 96-well plate, which
was incubated for 24 hours. The cells were then treated
with various concentrations of oxaliplatin, and incubated
for an additional hour at 37°C. Subsequently, 10 Lo f
MTT at a concentration of 5 mg/mL was added to each
well and cells were incubated for an additional 4 hours to
6 hours. The supernatant was aspirated and 100 Lo f
dimethylsulfoxide was added to the wells to dissolve any
precipitate present. The optical density was then mea-
sured at a wavelength of 570 nm by using an ELX800 plate
reader (Bio-Tek Instruments, Inc., Winooski, Vermont).
Surgical Protocol
The rats were anesthetized throughout the procedures
with 1.5% isoflurane (Abbott Laboratories, North Chicago,
IL) and oxygen, and surgery was performed under sterile
conditions. One 5-mm trocar (camera port) was intro-
duced in the middle lower abdomen with an open tech-
nique, and pneumoperitoneum was created with carbon
dioxide insufflation up to a pressure of 4 mm Hg. Two
additional “ports” (2-mm trocars) were inserted in the left
and right upper abdominal quadrant under direct vision
(Figure 1). Following gas insufflation and trocar place-
ment, 1x10
7 LMCR cells in 5 mL PBS were injected in the
peritoneal cavity under laparoscopic vision through the
16-gauge needle attached to a 10 mL syringe. After 10
minutes, the two 2-mm trocars were removed and carbon
dioxide insufflation was continued at a rate of 0.4 liters/
minute and a pressure of 4 mm Hg for an additional 5
Figure 1. Pictures of the position of trocar placement.
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sites. Oxaliplatin (0.198 mg/kg), 200 La ta5 0 0M
concentration, was then applied topically via an intramus-
cular injection to one 2-mm trocar site (right side) by using
a 27-gauge insulin syringe. The other port site was left
untreated as the control. The ports were then closed with
sutures. After 1 week, the rats were euthanized, and the
abdomen was examined for the presence of tumor. The
port sites were histologically examined for evidence of
metastases.
Statistical Analysis
The frequency of port-site tumor development was com-
pared between groups using the Fisher’s exact probability
test. Probabilities less than 0.05 were considered signifi-
cant.
RESULTS
Cytotoxicity Following 1-Hour Exposure
to Oxaliplatin
The cytotoxic effect of different concentrations of oxali-
platin is illustrated in Figure 2. All 3 cell numbers gave us
the similar IC50 (1-hour exposure) values at 100-micro-
mole oxaliplatin.
To determine the concentration of oxaliplatin with a 100%
cytotoxic effect on LMCL (-) cells, we performed another
in vitro study using oxaliplatin at 50 m, 100 m, and 500
m concentrations. In the wells exposed to 500 m, about
95% of the cells died. We therefore chose the 500 M
concentration of oxaliplatin (0.198 mg/kg) as our treat-
ment dose.
Necropsy and Microscopic Findings
All rats survived for the duration of the study. During the
autopsy, tumor was visible or palpable at the control port
sites. All rats developed severe carcinomatosis in the ab-
dominal cavity, including ascites in some cases. Macro-
scopically, the treated port site appeared to have a lower
incidence of tumor nodule (Figure 3). Microscopically,
neoplastic cells were present individually or arranged in
small aggregates or short cords. Neoplastic cells showed
moderate to marked pleomorphism and had eosinophilic
cytoplasm and normal to slightly hyperchromatic nuclei.
Inflammation associated with tumor cells was generally
mononuclear (plasma cells, lymphocytes, and few macro-
phages). In some areas, chronic active inflammation or
granulomatous inflammation was seen. This was most
likely due to the introduction of hairs into the tissue
during the surgical procedure (Figure 4).
Frequency of Port-Site Tumor Implantation
We observed that the number of animals with port-wound
tumors was not significantly lower at the oxaliplatin
treated port sites compared with the untreated group in
the muscle layer (P0.1) (Figure 5). In the subcutaneous
tissue, cancer cells were seen in 6 of 19 (32%) treated sites
compared with 7 of 19 (37%) in the untreated ports (P1).
In the deep border skeletal muscle, cancer cells were seen
in 13 of 19 (68%) treated ports and 14 of 19 (74%) un-
treated ports (P1). Tumor growth was not significantly
reduced in the subcutaneous tissue or the deep border
skeletal muscle as a result of oxaliplatin treatment.
Figure 2. Inhibition of LMCR-dimethylhydrazine induced BDIX
rat colonic adenocarcinoma on different oxaliplatin level.
Figure 3. Gross findings during autopsy. Arrow indicated the
port-site metastases.
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The cause and real incidence of port-site tumor recur-
rences remain unknown, and therefore, efficient ways of
prevention are still evolving. On anatomical grounds, it is
unlikely that port tumors are the result of hematogenous
or lymphatic spread. Direct implantation of tumor cells in
the port-site or wound is the most likely mechanism.16
Even though many surgeons still question the clinical
significance of metastases arising in trocar wounds follow-
ing laparoscopic intervention for malignancies, increasing
evidence, both clinical and experimental, suggests a need
for greater caution regarding its application to malignant
growth.13 It has been postulated that wound metastasis
occurs as a result of contamination following laparoscopic
manipulation of malignant tumors, with resultant spread
to abdominal wall wounds by direct transfer when trocars
and instruments are withdrawn from the peritoneal cavi-
ty.22 In this instance, the development of barrier strategies
to protect the wounds during laparoscopic surgery is sup-
posed to be sufficient to overcome the problem. How-
ever, it is also possible that the insufflation gas used
during laparoscopy mobilizes free cancer cells inside the
abdominal cavity and thereby transfers them to the
wounds without any direct physical contact with contam-
inated instruments. In our animal model, we were able to
observe how it is possible for cancer cells to become
implanted while the pneumoperitoneum is maintained
after trocar removal. A variety of methods have been
proposed to minimize the likelihood of port-site tumor
implantation; ie, wound protectors, impermeable speci-
men retrieval bags, and cytotoxic or cytolytic irriga-
tions,11,17,23 but only one study has been performed to test
the efficacy of direct injection of a cytotoxic agent. This
study used intraperitoneal povidone-iodine and an appro-
priate dose of intraperitoneal or intramuscular methotrex-
ate to demonstrate that a reduction in the incidence of
port-site metastases might be achieved by the injection of
appropriate tumoricidal agents.15 In this study, IM meth-
otrexate injection over the port site can reduce the num-
ber of port sites with tumor presentation from 74% to 39%,
comparable with our result from 68% to 37%.
Oxaliplatin is a third-generation platinum derivative
whose mechanism of action is similar to that of cisplatin.
Oxaliplatin (l-OHP) differs from cisplatin by the presence
of a diaminocyclohexane ligand in its chemical structure.
This important difference in the molecule, and hence in
the DNA adducts formed, confers a different spectrum of
activity when compared with cisplatin.24 Oxaliplatin is an
active drug in the treatment of advanced colorectal carci-
noma that is either chemotherapy naı ¨ve or refractory to
5-FU. In advanced colorectal cancer, 2 randomized studies
Figure 5. Port-site tumor incidence. *P0.1.
Figure 4. Upper panel (arrow) revealed the tumor cells in the
peritoneum (100x H&E staining), lower panel (arrow) showed
the tumor growth within the muscle (50x H&E staining).
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tion of oxaliplatin, fluorouracil (FU), and leucovorin (LV)
as first-line treatment compared with 5-FU and LV
alone.25,26 Oxaliplatin has been licensed in Europe since
1999, but it only gained FDA approval in the United States
in August of 2002. Accordingly, we chose to study oxali-
platin as a possible cytotoxic agent to prevent port-site
metastases. It is critical to determine the correct dosage of
oxaliplatin to be used to enable the success of this mo-
dality of treatment. Therefore, we performed an in vitro
study to test the cytotoxicity effect of this drug on the
cancer cell line we used in our animal model and deter-
mine the concentration to be used in vivo. No necrosis
was observed at the injection site based on the necropsy
and our pathology findings. This proved that the dose of
oxaliplatin chosen was not toxic to the tissues. The results
of the current study cannot demonstrate a significant re-
duction in the incidence of tumor metastases in the treated
muscle layer. There was no statistical significance be-
tween the treatment and control port sites (P0.1). This
suggests that the sample sizes were not enough or the
dose of oxaliplatin that we applied in this study was too
low. Nevertheless, we can still see some trend of declina-
tion of caner growth in the muscle layer. This suggests that
probably an effective dose of oxaliplatin applied via an
intramuscular injection may reduce the number of viable
tumor cells in the muscle layer and prevent metastasis to
develop from implanted viable cells into port-site
wounds. The results also suggest that it is difficult to
control cancer cell growth in all layers of the abdominal
wall using a port-site injection of an anticancer drug. To
solve this problem of drug delivery to other layers, the use
of a biodegradable polymer27 may be a more suitable
alternative to injection.
CONCLUSION
Topical oxaliplatin might not be useful in reducing the
incidence of port-site metastasis in our small number an-
imal study. Nonetheless, further studies are needed to
improve its method of application and dosage to verify
whether this cytotoxic agent can be successfully applied
to clinical practice.
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